Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-25 @ 1:25 AM
Ignite Modification Date:
2025-12-25 @ 1:25 AM
NCT ID:
NCT02439593
Eligibility Criteria:
Inclusion Criteria:
1. Patients of locally advanced pancreatic cancer with
* Major venous infiltration / thrombosis of the portal vein or superior mesenteric vein extending for several centimeters
* Tumor encasement (≥180°) of the superior mesentric artery or proximal hepatic artery
* Tumor abutment (\<180°) of the celiac trunk
* Tumor invasion of the aorta
* Presence of metastasis to lymph nodes beyond the field of resection
2. Histopathologically proven ductal adenocarcinoma of the pancreas (biopsy /cytology)
3. Eastern Cooperative Oncology Group (ECOG) performance scale 0 and 1
4. Age: 18 to 80 years
5. At least one of the diameters of the primary tumor or regional lymph node or both should be greater than 4 cm, as confirmed on contrast-enhanced computed tomography (CECT).
6. Patients, have primary tumor or regional lymph node or both lesser than 4 cm, as confirmed on CECT but have specific medical contraindications to stereotactic body radiation therapy or irreversible electroporation or as per patient's preference could be considered for HEATPAC.
7. No evidence of any distant metastasis
8. Patients with microscopic peritoneal carcinomatosis, detected on laparoscopy following 4 cycles on neo-adjuvant FOLFIRINOX would be included.
9. Estimated life expectancy of at least 6 months
10. Adequate kidney functionality defined as creatinine clearance \>50ml/min
11. Adequate liver functionality defined as total bilirubin ≤ 2x of the upper limit of normal
12. Adequate bone marrow reserves: White blood cell count ≥ 2.5 x 10˄9/L, Platelet count ≥ 100 x 10˄9/L, Hemoglobin ≥ 8.0g/L
13. Women of child-bearing age must secure sufficient contraception control during the clinical trial and six months after the clinical trial is completed
14. For females of child bearing potential, negative pregnancy test within 2 week prior to randomization.
15. Female patients should not be lactating
16. Absence of psychological, familial, sociological or geographical condition that could potentially hamper compliance with the study protocol and follow-up schedule
Exclusion Criteria:
1. Histopathology other than ductal adenocarcinoma pancreas
2. Prior radiotherapy to the site of treatment
3. Patients with unequivocal distant metastasis including liver
4. Patients with gross peritoneal carcinomatosis on laparoscopy
5. No prior or concurrent malignancies other than surgically treated squamous cell or basal cell carcinoma of the skin
6. No serious medical illness which would prevent informed consent or limit survival to less than 2 years
7. Active uncontrolled bacterial, viral or fungal infections until these conditions are corrected or controlled.
8. Psychiatric or addictive disorders or other conditions that would preclude the patient from meeting the study requirements.
9. Patients having metal implants, pacemakers or clustered markers.
10. Metallic endobiliary stenting would be a contraindication, hence plastic stents may be used if biliary drainage is indicated.
11. Patient with a history of myocardial infarction within the past 12 months
12. No connective disease disorders that contraindicate radiotherapy, e.g., Scleroderma
13. Pre-existing grade 2 peripheral neuropathy
14. Any known contraindication or hypersensitivity to the chemotherapeutic agents
15. Pregnancy, lactation period or lack of reliable contraception
16. Any other disease or therapy, which, present a risk to the patient or which are not compatible with the aims of the clinical trial
17. Patients would express their inability to travel on their own to Kantonsspital Aarau, (KSA) for hyperthermia treatment
18. Indications that the person concerned will be noncompliant to the clinical trial plan because of unwillingness to cooperate or difficulties in keeping the check-up appointments
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Maximum Age:
80 Years
Study:
NCT02439593
Study Brief:
Protocol Section:
NCT02439593